| Project/Area Number |
24591925
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
SEKI Naoko 久留米大学, 医学部, 講師 (40226634)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TOH Uhi 久留米大学, 医学部, 講師 (60268901)
FUJII Teruhiko 久留米大学, 医学部, 准教授 (50199288)
KAGE Masayoshi 久留米大学病院, 教授 (80148840)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 癌 / 免疫学 / 乳癌 / 免疫 |
|---|
| Outline of Final Research Achievements |
Cancer testis (CT)-antigens were expressed in a large proportion of triple negative (TN)- and ALDH-1 positive breast cancer specimens.
NY-ESO-1, MAGE-A10, and MAGE-C1 antigens were immunohistochemically expressed in 6%, 15%, and 12% of patients with primary invasive breast carcinoma, respectively. NY-ESO-1 and MAGE-A10 were preferentially expressed in TN or estrogen receptor negative breast cancers (p<0.05). ALDH-1 expression, which have been reported as predictive marker of cancer stem cells in terms of resistance to chemotherapy, was observed in 22% of tumor specimens, and was most prevalent in the TN breast cancers (p<0.001). Moreover, 41% of ALDH-1 positive specimens were accompanied with expression of any of CT-antigens, some of which showed concomitant expression of CT-antigens and ALDH-1.
Because of the limited therapeutic modalities for these phenotypes, significance of CT-antigens expressions should be further studied for beneficial immunotherapy in breast cancer patients.
|
